Response of VEGF and AT-II to HCG in PCOS

NCT ID: NCT02265861

Last Updated: 2014-10-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-01-31
• Study Completion Date: 2012-12-31

Brief Summary

This research is to investigate the response of vascular active factors, vascular endothelial growth factor (VEGF) and angiotensin-Ⅱ (AT-Ⅱ) to ovary stimulation during 24h in patients with polycystic ovary syndrome (PCOS).Controled prospective clinical study involved 60 women undergoing in vitro fertilization. Fifty-two patients with PCOS and 8 control cases were stimulated with human chorionic gonadotropin (HCG) during the early follicular phase of the menstrual cycle (4st to 7th days of the cycle).The blood was sampled before the injection (0 hour) and at the 3, 6, 12, 18 and 24 hours points after the stimulation. VEGF, AT-Ⅱ were measured by radioimmunoassay.

Detailed Description

After ovary stimulation, the level of VEGF in typical PCOS patients is obviously increased at the 3hs time point (p<0.05), while there is no difference with VEGF at all other time point among the four groups. As for AT-Ⅱ, before and after the ovary stimulation, at all time points, the AT-Ⅱ levels in serum of patients with different phenotypes of PCOS by Rotterdam criteria are all higher than the controls without PCOS. After the ovary stimulation, AT-Ⅱ in typical PCOS patients is obviously increased at 3hs time point, p<0.05. The response of VEGF and AT-Ⅱ to HCG in women with typical PCOS is higher in 24 hours after the stimulation during the early follicular phase. The response to the stimulation is different in patients with different phenotypes of PCOS by Rotterdam criteria. Serum VEGF and AT-Ⅱ levels as a possible contributor to a great risk of developing OHSS in patients with typical PCOS during the early follicular phase in 24 hours after the ovary stimulation.

Conditions

Polycystic Ovary Syndrome

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Group 1

typical PCOS

Group Type: EXPERIMENTAL

HCG

Intervention Type: DRUG

Group 2

PCOS without PCO

Group Type: EXPERIMENTAL

HCG

Intervention Type: DRUG

Group 3

PCOS without HA

Group Type: EXPERIMENTAL

HCG

Intervention Type: DRUG

Group 4

Control

Group Type: EXPERIMENTAL

HCG

Intervention Type: DRUG

Interventions

HCG

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• A total of 60 women were recruited and divided into four groups by Rotterdam criteria according to three typical characters:

1. biochemical characteristics of hyperandrogenism (HA)

2. chronic anovulation

3. polycystic ovary morphology (PCO).

Exclusion Criteria

• All women were matched for age (<35 yr).
• All subjects were screened, and no other endocrine disturbances (thyroid, adrenal) or medical illnesses were found.
• All the patients did not have any hormonal preparation during the 3 months preceding the study.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Nanjing University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Wang Yong

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

References

Qu J, Che Y, Xu P, Xia Y, Wu X, Wang Y. The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome. Int J Fertil Steril. 2015 Jan-Mar;8(4):373-8. doi: 10.22074/ijfs.2015.4176. Epub 2015 Feb 7.

Reference Type: DERIVED

PMID: 25780518 (View on PubMed)

Other Identifiers

NanjingUSMwy

Identifier Type: -

Identifier Source: org_study_id